Fresenius SE & Co. KGaA

Company Overview

Fresenius SE & Co. KGaA is a global healthcare group that provides critical products and services for treating and caring for critically and chronically ill patients. It offers a range of healthcare products, including Levothyroxine Sodium for Injection, a treatment for hypothyroidism, and Lodixanol Injection, USP, a contrast agent for diagnostic imaging. The company provides innovative solutions across various therapeutic areas, supporting patient care in chronic conditions and medical diagnostics. Fresenius operates in over 60 countries through its subsidiaries, and it also has an international distribution network and over 50 production sites.

Financial Highlights (FY 2024)

Company's Business Segments

• Fresenius Kabi : This segment includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
• Fresenius Helios : It is Europe’s leading private healthcare service provider, and its portfolio includes Helios Germany, Helios Spain, and Eugin Group (which was sold on January 31, 2024).
• Fresenius Vamed : This segment manages projects and provides services for hospitals and other healthcare facilities internationally. The services cover the entire value chain, from development, planning, and turnkey construction to maintenance, technical management, total operational management, and higher services.